default author photo

Volker Gerdts

University of Saskatchewan - Vaccine and Infectious Disease Organization

SCHOLARLY PAPERS

4

DOWNLOADS

299

TOTAL CITATIONS

0

Scholarly Papers (4)

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 28 Posted: 21 Aug 2024
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 119 (602,987)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 33 Posted: 08 Aug 2025
University of Saskatchewan - Vaccine and Infectious Disease Organization, affiliation not provided to SSRN, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 51 (1,072,374)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

2.

Efficacy of a Stable Broadly Protective Subunit Vaccine Platform Against Sars-Cov-2 Variants of Concern

Number of pages: 43 Posted: 18 Apr 2024
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Vaccine Formulation Institute (VFI), University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 55 (1,010,164)

Abstract:

Loading...

SARS-CoV-2, subunit vaccine, broad protection, vaccine platform, emerging coronaviruses, Syrian hamsters

3.

Male Sex and Age Biases Viral Burden, Viral Shedding, and Type 1 and 2 Interferon Responses During SARS-CoV-2 Infection in Ferrets

Number of pages: 33 Posted: 25 Jan 2021
Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Case Western Reserve University, Dalhousie University - Faculty of Medicine, Dalhousie University, Dalhousie University, Dalhousie University, University of Arkansas for Medical Sciences, Department of Microbiology and Immunology, University of Manitoba - Department of Infectious Diseases and Medical Microbiology, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan and Canadian Centre for VaccinologyDalhousie University - Department of Pediatrics
Downloads 48 (1,086,013)

Abstract:

Loading...

4.

Immunogenicity of Convalescent and Vaccinated Sera Against Clinical Isolates of Ancestral SARS-CoV-2, Beta, Delta, and Omicron Variants

Number of pages: 21 Posted: 10 Feb 2022
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Laboratory of Shenzhen Children’s Hospital, University of Toronto - Sunnybrook Research Institute, Dalhousie University, University of Toronto - Sunnybrook Research Institute, University of Saskatchewan, Students, University of Saskatchewan, Students, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Toronto - Department of Medicine, Mount Sinai Health System, Mount Sinai Health System, Mount Sinai Health System, University of Toronto - University Health Network, University of Toronto - Mount Sinai Hospital, Toronto, Mount Sinai Health System, University of Toronto - Department of Laboratory Medicine and Pathobiology, Sinai Health System TorontoUniversity of Toronto - Centre for Global Health Research, University of Toronto, University of Toronto - Sunnybrook Research Institute and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 26 (1,372,601)

Abstract:

Loading...

SARS-CoV-2, neutralization, variants of concern, omicron, vaccine, neutralizing antibodies